• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

Omeros Corp (OMER)

Common Shares
Sell: $11.85|Buy: $11.95|Change: 0.39 (3.39%)

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Company profile

Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediateddiseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.

Address

201 Elliott Avenue West
Seattle
WA
USA
98119

Telephone

+1 206 676-5000

Website

https://www.omeros.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Omeros Corp Fourth Quarter Earnings Conference Call for 20262027-03-31T16:30:00
Omeros Corp Fourth Quarter Earnings Results for 20262027-03-31T00:00:00
Omeros Corp Annual Report for 20262027-03-31T00:00:00
Omeros Corp Third Quarter Earnings Conference Call for 20262026-11-13T16:30:00
Omeros Corp Third Quarter Earnings Results for 20262026-11-13T00:00:00
Omeros Corp Second Quarter Earnings Conference Call for 20262026-08-14T16:30:00
Omeros Corp Second Quarter Earnings Results for 20262026-08-14T00:00:00
Omeros Corp Annual General Meeting for 20262026-06-26T10:00:00
Omeros Corp First Quarter Earnings Conference Call for 20262026-05-15T16:30:00
Omeros Corp First Quarter Earnings Results for 20262026-05-15T00:00:00

Previous key dates

NameKey Date
Omeros Corp Fourth Quarter Earnings Conference Call for 20252026-03-31T16:30:00
Omeros Corp Fourth Quarter Earnings Result for 20252026-03-31T00:00:00
Omeros Corp Annual Report for 20252026-03-31T00:00:00
Omeros Announces New Date for YARTEMLEA® Approval Conference Call2026-01-07T16:30:00
Omeros Corp Third Quarter Earnings Conference Call for 20252025-11-13T16:30:00
Omeros Corp Third Quarter Earnings Results for 20252025-11-13T00:00:00
Omeros Corp Second Quarter Earnings Conference Call for 20252025-08-14T16:30:00
Omeros Corp Second Quarter Earnings Results for 20252025-08-14T00:00:00
Omeros Corp Annual General Meeting for 20252025-06-27T10:00:00
Omeros Corp First Quarter Earnings Conference Call for 20252025-05-15T16:30:00
Omeros Corp First Quarter Earnings Result for 20252025-05-15T00:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2026 AJ Bell. All rights reserved.